These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 21248115)
1. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115 [TBL] [Abstract][Full Text] [Related]
2. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
3. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998 [TBL] [Abstract][Full Text] [Related]
4. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485 [TBL] [Abstract][Full Text] [Related]
5. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224 [TBL] [Abstract][Full Text] [Related]
6. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001 [TBL] [Abstract][Full Text] [Related]
7. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779 [TBL] [Abstract][Full Text] [Related]
8. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366 [TBL] [Abstract][Full Text] [Related]
9. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649 [TBL] [Abstract][Full Text] [Related]
10. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? Gillardon F J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277 [TBL] [Abstract][Full Text] [Related]
12. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006 [TBL] [Abstract][Full Text] [Related]
13. Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. Skibinski G; Nakamura K; Cookson MR; Finkbeiner S J Neurosci; 2014 Jan; 34(2):418-33. PubMed ID: 24403142 [TBL] [Abstract][Full Text] [Related]
14. A Drosophila model for LRRK2-linked parkinsonism. Liu Z; Wang X; Yu Y; Li X; Wang T; Jiang H; Ren Q; Jiao Y; Sawa A; Moran T; Ross CA; Montell C; Smith WW Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2693-8. PubMed ID: 18258746 [TBL] [Abstract][Full Text] [Related]
15. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity. Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464 [TBL] [Abstract][Full Text] [Related]
16. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188 [TBL] [Abstract][Full Text] [Related]
17. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620 [TBL] [Abstract][Full Text] [Related]
18. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966 [TBL] [Abstract][Full Text] [Related]
19. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models. Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328 [TBL] [Abstract][Full Text] [Related]
20. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. Plowey ED; Cherra SJ; Liu YJ; Chu CT J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]